Spinocerebellar ataxias: prospects and challenges for therapy development

Keyphrases

• Spinocerebellar Ataxia 100%
• Therapy Development 100%
• Clinical Trials 20%
• Therapeutic Strategies 20%
• Polyglutamine 20%
• United States 10%
• Neurodegenerative Diseases 10%
• Natural History 10%
• Disease Progression 10%
• Pathogenic Mechanism 10%
• Mutant Protein 10%
• Gene Silencing 10%
• Successful Therapy 10%
• Autosomal Dominant 10%
• Disease Activity 10%
• Disease Stage 10%
• Magnetic Resonance Spectroscopy 10%
• Therapeutic Trial 10%
• CAG Repeat 10%
• United Europe 10%
• Data Sharing 10%
• Emerging Therapeutics 10%
• Clinical Outcome Measures 10%
• Disease-modifying Therapy 10%
• Progressive Ataxia 10%
• Mutant RNA 10%
• Target Engagement 10%
• Pre-manifest 10%
• Premanifest 10%
• Disease-specific Biomarker 10%
• Responsiveness to Change 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Spinocerebellar Degeneration 100%
• Diseases 30%
• Clinical Trial 20%
• Biological Marker 20%
• Polyglutamine 20%
• Combination Therapy 10%
• Disease Exacerbation 10%
• Disease Activity 10%
• Ataxia 10%
• Mutant Protein 10%

Neuroscience

• Spinocerebellar Ataxia 100%
• Polyglutamine 20%
• Neurodegenerative Disorder 10%
• Nuclear Magnetic Resonance Spectroscopy 10%
• Magnetic Resonance Imaging 10%
• Ataxia 10%
• Gene Inactivation 10%
• CAG Repeat 10%
• Mutant Protein 10%